The researchers found that 8.2% of patients reported treatment-emergent adverse events (TEAEs), the most common were application site dermatitis, paresthesia, pain, and pruritus. Several authors disclosed financial ties to Allergan, which is a manufacturer of oxymetazoline.
The average improvement was 53.9%. Reported side effects included mild edema, mild-to-moderate erythema, and mild-to-moderate bruising.
Ivermectin cream is a semi-synthetic derivative isolated from the fermentation of Streptomyces avermitilis that belongs to the avermectin family of macrocyclic lactones.
The researchers found that patients' out-of-pocket spending for topical steroids was $333.7 million. There was a 226.5% increase in total annual spending, from $237.6 million to $775.9 million.
Rhofade applied once-daily demonstrated a reduction in persistent facial erythema associated with rosacea through 12 hours in both clinical trials.
Allergan announced that the Food and Drug Adminisration (FDA) has approved Rhofade (oxymetazoline HCl) cream for the topical treatment of persistent facial erythema associated with rosacea in adults.
For patients with rosacea, phenotype-based treatments should be given for presenting signs and symptoms, according to updated treatment guidelines published online in the British Journal of Dermatology.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for oxymetazoline HCl cream 1% (Allergan) for the treatment of persistent facial erythema associated with rosacea in adults.
For patients with rosacea, ivermectin treatment is associated with long-term improvement in health-related quality of life (HRQoL).
Rosacea is associated with an increased risk for Parkinson's disease, according to research published online in JAMA Neurology.
Recurrent superficial cellulitis-like erythema is associated with Helicobacter cinaedi (H. cinaedi) bacteremia, according to a case report published online in The Journal of Dermatology.
Dr. Reddy's Laboratories announced that the Food and Drug Administration (FDA) has granted tentative approval for Zenavod (doxycycline) capsules for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adults.
Bayer HealthCare announced the launch of Finacea Foam (azelaic acid) 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
Rosacea is associated with various comorbid conditions, including, but not limited to, allergies, respiratory diseases, and gastrointestinal diseases.
Risk of rosacea appears to be half environmental and half genetic, with sun exposure, body mass index, smoking, alcohol consumption, and cardiovascular comorbidity key contributors.
Bayer HealthCare announced that the Food and Drug Administration (FDA) has approved Finacea (azelaic acid) Foam 15% for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea.
For patients with papulopustular rosacea (PPR), once-daily ivermectin 1 percent cream (IVM 1 percent) is superior to twice-daily metronidazole (MTZ 0.75 percent) cream, according to a new study.
Galderma announced that the Food and Drug Administration (FDA) has approved Soolantra (ivermectin) Cream for the topical treatment of inflammatory lesions of rosacea.
Quest Products announced the launch of ProVent Rosacea Moisturizing Creme indicated to help reduce the appearance of skin often associated with rosacea and other skin conditions.
Galderma announced results from two Phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopusular rosacea.
Galderma has announced that in a one-year, open-label, non-comparative study, Mirvaso (brimonidine) topical gel was demonstrated to be safe and effective when used once daily for up to 12 months.